TERT and metastatic malignant neoplasm in the lymph nodes: Interestingly, no impact of TERT amplification on patient survival in patient cohorts with high T-stage (pT2-4N0-3), without lymph node metastases (pT0-4N0), or with lymph node metastases (pT0-4N1-3) could be detected (p(pT2-4N0-3) = 0.241, p(pT0-4N0) = 0.181, p(pT0-4N1-3) = 0.257, Fig. 1B–D).